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Abstract 6a-Hydroxylup-20(29)-en-3-on-28-oic acid (1), a natural triterpenoid, was found to possess the ability in a
dose-dependent manner inhibiting hormone-induced adipocyte differentiation in 3T3-L1 preadipocytes, and restoring
glucose consuming ability in dexamethasone (DXM)-induced insulin resistant 3T3-L1 adipocytes. Compound 1 was also
found to ameliorate DXM-induced adipocyte dysfunction in lipolysis and adipokine secretion. Mechanistic studies
revealed that 1 inhibited adipocyte differentiation in 3T3-L1 preadipocytes via down-regulating hormone-stimulated gene
transcription of peroxisome proliferator-activated receptor c and CCAAT-enhancer-binding protein alpha which are key
factors in lipogenesis, and restored DXM-impaired glucose consuming ability in differentiated 3T3-L1 adipocytes via
repairing insulin signaling pathway and activating down-stream signaling transduction by phosphorylation of signaling
molecules PI3K/p85, Akt2 and AS160, thus leading to increased translocation of glucose transporter type 4 and trans-
portation of glucose.
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Keywords 6a-Hydroxylup-20(29)-en-3-on-28-oic acid  3T3-L1  Adipocyte differentiation  Dexamethasone-
induced insulin resistance  Adipocyte dysfunction  PI3K/Akt2 signaling
1 Introduction
Obesity and obesity-induced insulin resistance increases the
likelihood of major diseases referred as metabolic syndrome,
such as heart disease, type 2 diabetes, stroke, etc. [1, 2].
Hypertrophic adipocytes in obesity release excess lipolytic
products into blood, resulting in pathological changes and
functional damage to organ tissues including pancreas, and
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insulin resistance and type 2 diabetes [3, 4]. In addition,
adipose tissue in obesity secrets elevated level of proin-
flammatory adipokines such as leptin, tumor necrosis factor-
a (TNF-a) and interleukins (ILs) but lowered level of anti-
inflammatory cytokine such as adiponectin, resulting in
metabolic disorder and chronic inflammation of the body [5,
6]. Abnormally secreted adipokines may also reduce insulin
sensitivity of target tissues by impairing insulin signaling
transduction [6, 7]. Insulin resistance is characterized by
reduced glucose uptake by target tissues or cells (adipose,
muscle, liver) owing to impaired insulin signaling trans-
duction and/or glucose transporting ability. In adipocyte,
inactivation of insulin signaling molecules such as IR,
insulin receptor substrate (IRS), PI3K and Akt, especially the
down-stream PI3K and Akt, reduces the translocation of
intracellular glucose transporter 4 (GLUT4) to plasma
membrane and consequently impairs the glucose transport-
ing ability of the cell [8]. Chinese herbal medicines con-
tribute greatly to the research and development of new drugs.
Structurally diverse compounds with bioactivities in reduc-
ing blood lipid and glucose level, or prevention of cardio-
vascular and metabolic diseases have been discovered, such
as stilbenoids from Polygonum multiflorum and flavonoids
from Crataegus pinnatifida [9, 10]. In our attempt to search
natural components with hypoglycemic or hypolipidemic
potential, 6a-hydroxylup-20(29)-en-3-on-28-oic acid (1) - a
lupane type triterpenoid from Viburnum odoratissimum—
was found to be able to enhance glucose uptake in dexam-
ethasone-induced insulin resistant 3T3-L1 adipocytes and
HepG2 cells [11]. Further investigations were then con-
ducted and here we give a detail report for the effects and
working mechanisms of 1 on hormone-stimulated adipoge-
nesis, and dexamethasone-induced insulin resistance and
adipocyte dysfunction. Rosiglitazone, which is an insulin
sensitizer working as agonist of peroxisome proliferator-
activated receptor c, was used as the drug control.
2 Results and Discussion
2.1 Compound 1 Inhibited ‘‘Hormone Cocktail’’-
Induced Adipocyte Differentiation and Lipogenesis
in 3T3-L1 Preadipocytes
In an 48-h proliferation assay, 1 at 20, 10 or 5 lM did not
affect the viability of 3T3-L1 preadipocytes (Fig. 1), but in
‘‘hormone cocktail’’-induced adipocyte differentiation, 1
dose-dependently reduced the staining of cells by Oil red
O, indicating inhibited adipocyte differentiation. Differ-
entiation ratio of 3T3-L1 preadipocytes in the presence of
20, 10 or 5 lM of 1 was remarkably decreased from 100 %
of the control to 36.8, 57.1 or 81.7 % (P\ 0.001 each),
respectively (Fig. 2). In this experiment, rosiglitazone at
20 lM enhanced adipocyte differentiation as expected.
Triglyceride (TG) is the indicator of lipogenesis in fat
cell. Synthesis of TG by cultural fat cells relies on the
decomposition of glucose to generate free fatty acids
(FFAs). Glucose utilization and FFA production are
therefore indirect indicators for lipogenesis. As shown in
Fig. 3, glucose remaining in culture medium of 3T3-L1
cells with differentiation induction was much less than that
in medium of cells without induction (6.0 mM vs.
13.6 mM, P\ 0.001), implying stimulated glucose uti-
lization and lipogenesis in adipocyte differentiation.Unlike
rosiglitazone which stimulated the glucose utilization and
TG synthesis, 1 at 20 or 10 lM increased the glucose
remaining (P\ 0.01 or 0.05), as a result, reduced FFA
production (P\ 0.01 each) and cellular TG content
(P\ 0.001 or 0.01) of induced cells, showing inhibitory
effect on ‘‘hormone cocktail’’-induced adipocyte differen-
tiation and lipogenesis.
2.2 Compound 1 Inhibited ‘‘Hormone Cocktail’’-
Stimulated Gene Transcription of Peroxisome
Proliferator-Activated Receptor c (PPARc)
and CCAAT-Enhancer-Binding Protein Alpha
(C/EBPa)PPARc and C/EBPa
PPARc and C/EBPa are two key transcriptional factors in
adipocyte differentiation and lipogenesis, both express in
very low level in preadipocytes but are significantly up-
regulated in the process of adipocyte differentiation [12]. In
this study, gene transcription of PPARc and C/EBPa in 3T3-
L1 cells were remarkably stimulated by ‘‘hormone cocktail’’
(P\ 0.001 and 0.0001 vs. cells not induced), the addition of
rosiglitazone (a PPARc agonist) further stimulated the
expression of the two genes, but the addition of 1 (20 or
10 lM) into the differentiation medium caused marked
reduction in cellular mRNA levels of PPARc (P\ 0.05 vs.
induced cell control) and C/EBPa (P\ 0.01 or 0.05 vs.
induced cell control) (Fig. 4). As a result, fatty acid synthase
Fig. 1 Compound 1 did not affect the proliferation of 3T3-L1
preadipocytes. 3T3-L1 preadipocytes were incubated with different
concentrations of 1 for 48 h. Cell viability was measured by CCK-8
assay. Data were expressed as Mean ± SD of three independent
experiments
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(FAS), the key enzyme catalyzing the synthesis of FFA [13],
was suppressed by 1 (P\ 0.001) (Fig. 3). In this study, 1
inhibited hormone-stimulated adipocyte differentiation and
lipogenesis through down-regulating gene expression of
PPARc and C/EBPa, showing potential to deal with obesity
and obesity-related health problems.
2.3 Compound 1 Restored Glucose Consuming Ability
and Alleviated Dysfunction in Dexamethasone-
Induced Insulin Resistant 3T3-L1 Adipocytes
As mentioned above, obesity is a primary cause for
development of insulin resistance, and insulin resistance
always accompanies with metabolic disorder. In this study,
effect of 1 on improvement of glucose consuming ability
and metabolic disorder was investigated in insulin resistant
3T3-L1 adipocytes. Dexamethasone (DXM), which
impairs glucose transporting ability and causes insulin
resistance and metabolic disorder in adipose tissue and
adipocytes [14, 15], was used to induced insulin resistant
state of the cells.
Reduced glucose uptake is the character of insulin
resistance. In our study, 3T3-L1 adipocytes in the presence
of 1 lM DXM consumed much less glucose within 48 h
than cells in the absence of DXM (P\ 10-5), indicating
that insulin resistant state in 3T3-L1 adipocytes was suc-
cessfully induced by DXM treatment. 1 at 20 and 10 lM
enhanced the glucose consuming ability of DXM-treated
3T3-L1 adipocytes in a dose-dependent way (P\ 10-5 and
10-4) like rosiglitazone did, implying that 1 restored the
glucose transport ability of the cells (Fig. 5a).
Oversupplied lipolytic products contribute to insulin
resistance. In this study, effect of 1 on lipolysis in DXM-
treated 3T3-L1 adipocytes was monitored by measuring the
glycerol concentration in culture medium. Result showed
that, 3T3-L1 adipocytes in the presence of 1 lM DXM
released much more glycerol into medium within 48 h than
cells in the absence of DXM (P\ 0.001), indicating
stimulated lipolysis by DXM. Compound 1 and rosiglita-
zone at 20 lM reduced the glycerol concentration in
medium (P\ 0.05) (Fig. 5b), showing inhibitory effect on
DXM-stimulated lipolysis in 3T3-L1 adipocytes.
Fig. 2 Detection of differentiated 3T3-L1 adipocytes. 3T3-L1
Preadipocytes were maintained in growth medium (Undifferentiated),
or induced for adipocyte differentiation in the absence (Differentiated
control) or presence of various concentrations of 1 or rosiglitazone.
Differentiated adipocytes were stained red by oil red O. Pictures were
taken under an inverted microscope (9100). Absorption of Oil red O
for each treatment was measured at 492 nm (A492nm) after dissolving
the cellular Oil red O with isopropanol, differentiation rate (DR) was
calculated by equation DR (%) = 100 9 (ASample - AUndifferentiated)/
(ADifferentiated control - AUndifferentiated). *P\ 0.05, ***P\ 0.001
versus Differentiated control
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Overexpressed proinflammatory cytokines (TNF-a, IL-
6, leptin, etc.) and reduced expression of anti-inflammatory
cytokine (adiponectin) are responsible for chronic inflam-
mation and the development of insulin resistance [16]. It
was reported that obese mice lacking either TNF-a or IL-6
show protection against developing insulin resistance,
while chronic exposure to TNF-a, IL-6 or leptin activates
PTP1B gene and reduces the expression of IRS proteins in
myocytes or adipocytes of mice [17–19]. The anti-inflam-
matory cytokine adiponectin is specifically expressed by
adipocyte and directly sensitizes the body to insulin [20].
Lack of adiponectin causes obesity and contributes to
insulin resistance, type 2 diabetes, and the metabolic syn-
drome, while administration of adiponectin improves
insulin resistance [21, 22]. Our study showed that, 3T3-L1
adipocytes in the presence of 1 lM DXM secreted more
TNF-a (P\ 0.05) and IL-6 (P\ 0.01), but less leptin
(P\ 0.05) and adiponectin (P\ 0.05) (Fig. 6) into med-
ium than DXM-free ones, indicating severe disorder in
cytokine secretion was induced by DXM treatment. Com-
pound 1 at 20 lM significantly reduced the secretion
of TNF-a (P\ 0.05), IL-6 (P\ 0.001) and leptin
(P\ 0.001), and elevated the secretion of adiponectin
(P\ 0.05) in DXM treated 3T3-L1 adipocytes, showing
regulatory effect on DXM-induced adipocyte dysfunction
Fig. 4 Compound 1 down-regulated PPARc and C/EBPa gene
transcription in 3T3-L1 cells in the process of adipocyte differenti-
ation. 3T3-L1 preadipocytes were maintained in growth medium
(Preadipocytes) or induced for adipocyte differentiation in the
absence (Control) or presence of 1 or rosiglitazone for 8 days.
mRNA levels were analyzed by RT-PCR, and normalized using b-
actin. DDDP\ 0.001 and DDDDP\ 0.0001 versus Preadipocytes.
*P\ 0.05, **P\ 0.01 and ***P\ 0.001 versus Control
Fig. 3 Compound 1 reduced glucose utilization and lipogenesis of
3T3-L1 cells in adipocyte differentiation. 3T3-L1 preadipocytes were
induced for adipocyte differentiation for 8 days. Drug treatment was
performed from day 1 to 4. Medium was replaced every other day.
Glucose and FFA concentrations in medium on day 6 and cellular TG
and FAS contents on day 8 were measured by using the kits. Cellular
TG and FAS contents were normalized using total protein (TP). Data
were expressed as Mean ± SD of three independent experiments.
*P\ 0.05, **P\ 0.01 and ***P\ 0.001 versus Control.
DDDP\ 0.001 versus Not induced. Ros: rosiglitazone
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(Fig. 6) that was different from rosiglitazone. Rosiglita-
zone at 20lM remarkably increased the secretion of TNF-a
and IL-6 in 3T3-L1 adipocytes.
2.4 Compound 1 Repaired Insulin Signaling Pathway
and Activated PI3K/Akt2/AS160 Signaling
in DXM- Induced Insulin Resistant 3T3-L1
Adipocytes
In mature adipocytes, glucose uptake is carried out by
GLUT4 which is driven by insulin signaling transduction
that is activated by sequential posphorylation of insulin
signaling proteins, including IR, IRS1, PI3K and Akt2.
Phosphorylated Akt2 then stimulates the translocation of
intracellular GLUT4 vesicles to plasma membrane for
functioning as glucose transporters [23]. Inhibition of sig-
naling proteins leads to inhibited GLUT4 translocation and
weakened glucose transporting ability of cells [24]. In
which, the phosphorylation of down-stream PI3K/p85 and
Akt2 plays a key role in GLUT4 translocation [25]. AS160,
a substrate of Akt2, also regulates GLUT4 trafficking in
adipocytes. Nonphosphorylated AS160 binds to intracel-
lular GLUT4 vesicles and inhibits GLUT4 translocation,
and AS160 phosphorylation overcomes this inhibitory
effect [26]. Effects of 20 lM 1 on expression and/or
phosphorylation of IR, IRS1, PI3K, Akt2, GLUT4 and
Fig. 6 Compound 1 regulated cytokine secretion in DXM-treated
3T3-L1 adipocytes. Cells were incubated without 1 lM DXM
together with 20 or 10 lM 1 or 20 lM rosiglitazone (Ros) for 48 h.
Cytokine concentrations in culture medium were measured and
expressed as mean ± SD of three independent experiments.
DP\ 0.05 and DDP\ 0.01 versus DXM-free cells (Without DXM).
*P\ 0.05, **P\ 0.01, and ***P\ 0.001 versus 3T3-L1 cells with
DXM (Control)
Fig. 5 Compound 1 restored glucose consuming ability in DXM-
treated 3T3-L1 adipocytes and inhibited DXM-stimulated lypolysis.
Fully differentiated 3T3-L1 adipocytes were incubated with 1 or
rosiglitazone (Ros) in the presence of 1 lM DXM for 48 h. Glucose
and glycerol concentrations in medium were measured by using the
assay kits. Data were mean ± SD of three repeated experiments.
*P\ 0.05, ****P\ 10-4 and *****P\ 10-5 versus DXM-treated
cells (Control); DDDP\ 10-3 and DDDDDP\ 10-5 versus DXM-free
cells (Without DXM)
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AS160 in DXM-induced insulin resistant 3T3-L1 adipo-
cytes were investigated. Result showed that, in DXM-
treated 3T3-L1 adipocytes, expression of IR-a, IRS1,
PI3K/p85, Akt2 and GLUT4 was suppressed (Fig. 7a),
phosphorylation of down-stream proteins PI3K/p85, Akt2
and AS160 was obviously inhibited, while the phospho-
rylation of upper-stream proteins IR-b and IRS1 kept
unchanged (Fig. 7b). The addition of 20 lM 1 to DXM-
treated 3T3-L1 adipocytes elevated the expression of IR-a,
IRS1, Akt2 and GLUT4 (Fig. 7a), and increased the
phosphorylation of PI3K/p85, Akt2 and AS160, but did not
affect the phosphorylation level of IR-b and IRS1,
(Fig. 7b), showing activity similar to rosiglitazone. Result
suggested that, DXM impaired insulin signaling pathway
and reduced glucose consuming ability in 3T3-L1 adipo-
cytes not by inhibiting upper-stream IR signaling trans-
duction, but by directly inhibiting the down-stream PI3K/
Akt2/AS160 signaling, thus leading to reduced GLUT4
translocation and glucose transporting ability. Compound 1
ameliorated DXM-induced impairment on insulin signaling
pathway, and stimulated the phosphorylation of PI3K/
Akt2/AS160, showing potential to deal with DXM-induced
insulin resistance.
3 Experimental Section
3.1 Chemicals and Reagents
Cell counting kit-8 (CCK-8) was from Dojindo Molecular
Technologies, Inc. (Kumamoto, Japan). Oil red O staining
kit, FFA detection kit and TG assay kit were purchased
from Nanjing Jiancheng Bioengineering Institute (Nanjing,
China). Glycerol content GPO-POD enzymatic assay kit
was purchased from Applygen Technologies Inc, China.
ELISA kits for quantitative analysis of mouse TNF-a, IL-6,
adiponectin, leptin and FAS, rabbit anti-IR-a, goat anti-
rabbit IgG (c-chain specific) and goat anti-mouse IgG (c-
chain specific) were from Wuhan Boster Biotech Co., Ltd
(Wuhan, China). Insulin, 3-isobutyl-1-methylxanthine
(IBMX), DXM and antibody for mouse GLUT4 were
purchased from Sigma-Aldrich Chemical (St. Louis, MO,
USA). Antibodies for IRS1, phospho-IRS1 (Ser307), PI3K/
p85, phospho-PI3K/p85 (Tyr458)/p55 (Tyr199), Akt (pan),
phospho-Akt2 (Ser473) and phospho-AS160 (Thr642)
were purchased from CST China (Shanghai, China).
Enhanced BCA Protein Assay Kit, Cell lysis buffer, PVDP
membrane (0.45 lm), BeyoECL Plus were purchased from
Fig. 7 Compound 1 ameliorated DXM impaired insulin signaling
pathway in DXM-3T3-L1 adipocytes. 3T3-L1 adipocytes were
incubated with 1 lM DXM, with or without 20 lM 1 or 20 lM
rosiglitazone (Ros) for 48 h. DXM-free 3T3-L1 adipocytes were set
as insulin sensitive control. Protein expression was detected by
western blotting
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Beyontime Institute of Biotechnology (Shanghai, China).
Rosiglitazone was provided by Guangzhou Institute for
Drug Control (Guangzhou, China).
6a-Hydroxylup-20(29)-en-3-on-28-oic acid (1) was
obtained from Viburnum odoratissimum in our laboratory
[11]. It was dissolved in DMSO (20 mmol/L) and diluted
with cell growth medium for experimental usage.
3.2 Cell Line and Cell Culture
Murine preadipocyte cell line 3T3-L1 was kindly provided
by Prof. WF Fong of Hong Kong Baptist University, and
were grown in Dulbecco’s Modified Eagle’s Medium
containing 4.5 g/L of glucose and 10 % fetal bovine serum
(Gibco, Rockville, MD, USA), at 37 C, saturate humidity
and 5 % CO2.
3.3 Cell Proliferation Assay
3T3-L1 preadipocytes in 100 lL growth medium were
seeded in 96-well plates at a density of 5000 cells per well.
Twenty-four hours later, different concentrations of 1 were
added to the medium. After 48 h of incubation, cell via-
bility was measured by using CCK-8 assay kit.
3.4 Induction for Adipocyte Differentiation
3T3-L1 preadipocytes were induced for adipocyte differ-
entiation by the ‘‘hormone cocktail’’ [11]. Briefly, the 4th
generation cells were grown in growth medium until con-
fluence. Cells were induced for adipocyte differentiation in
growth medium containing 0.5 mM IBMX, 1 lM DXM
and 10 lg/mL insulin for 2 days, and in growth medium
containing 10 lg/mL insulin for another 2 days, and then
in drug free growth medium for 4 days. Medium was
replaced every 2 days. To investigate the effect of 1 on
‘‘hormone cocktail’’-induced adipocyte differentiation, 1 of
20, 10 or 5 lM, or rosiglitazone of 20 lM was added
together with the ‘‘hormone cocktail’’ on days 1–4.
3.5 Detection of Adipocytes
Differentiated adipocytes were detected by staining the
cellular lipid red with Oil red O [27]. After taking pictures
under an inverted microscope, cellular Oil red O was dis-
solved with certain volume of isopropanol. Absorbance
which is positively correlated to the rate of successful
differentiation was read at 492 nm.
3.6 Glucose Utilization, FFA and TG Synthesis
in Adipocyte Differentiation
In 12-well plates, 3T3-L1 preadipocytes were induced for
adipocyte differentiation for 8 days as described above,
with 1.5 mL medium per well. 1 of various concentra-
tions or rosiglitazone of 20 lM was added into the dif-
ferentiation medium on days 1–4. Supernatant medium on
days 6 was collected for measurement of glucose and
FFA by using glucose assay kit and FFA detection kit,
respectively. Cells on days 8 were washed with ice-cold
PBS trice and then repeatedly frozen and thawed at -80/
37 C until the cells were fully disrupted. After addition
of 100 uL of PBS, cells were shaved by Cell Scraper and
the mixed liquor was collected and centrifuged for 5 min
at 12.5 9 103 g. Supernatant was collected for assessment
of TG concentration by using the kit. Intracellular TG
content was normalized to the concentration of total
protein (TP) measured by using Enhanced BCA Protein
Assay Kit.
3.7 Measurement of Cellular FAS Content
In 6-well plates, 3T3-L1 preadipocytes were induced for
adipocyte differentiation for 8 days as described above.
Cells were washed with 2 mL PBS, lysed with 150 lL cell
lysis buffer on ice for 2 min. Cell lysate was collected by
centrifuge at 13.5 9 103 g for 5 min at 4 C. Content of
FAS was measured by using the kit, intracellular FAS level
was normalized to the content of total protein measured by
using the protein assay kit.
3.8 Glucose Consuming, Glycerol Releasing
and Adipokine Secretion in DXM-Induced Insulin
Resistant 3T3-L1 Adipocytes
In 6-well plates, fully differentiated 3T3-L1 adipocytes in
3 mL growth medium were incubated with 1 lM DXM for
48 h, with or without the addition of 20 or 10 lM of 1 or
20 lM of rosiglitazone. Supernatant medium was collected
by centrifuge. Concentrations of glucose, glycerol, leptin,
Table 1 Sequences of quantitative PCR primers for mouse genes
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adiponectin, TNF-a and IL-6 were measured by using the
kits.
3.9 RT-PCR Analysis
One microgram of total RNA was subjected to RT reaction
using Bestar qPCR RT Kit (DBI Bioscience, Lud-
wigshafen, Germany). RT reaction product was then
amplified by PCR with the gene specific primers listed in
Table 1 (Sangon Biotech, Shanghai, China) and Bestar
SybrGreen qPCRmaster Mix (DBI) at 94 C for 2 min,
94 C for 20 s, 58 C for 20 s, 72 C for 20 s, and 40
cycles. The gene expression levels were analyzed by a
StrataGene Mx3000P QPCR Real-Time PCR System
(Agilent) and normalized using b-actin. Results were
Mean ± SD from three independent experiments.
3.10 Western-Blot Analysis
Thirty micrograms of total protein were separated in 10 %
SDS–PAGE and electro-transferred to PVDF membranes.
After blocking with 5 % BSA, membranes were incubated
with primary antibodies in 2.5 % BSA, 0.3 % Tween-20
for 2 h at room temperature followed by corresponding
secondary antibodies for another 1.5 h at room tempera-
ture. Protein bands were visualized by ECL.
3.11 Statistical Analysis
All data are representative of three independent experi-
ments. Values are expressed as mean ± SD. Statistical
analyses were conducted using One-Way ANOVA. A
value of P\ 0.05 was considered to indicate statistical
significance.
4 Conclusion
6a-hydroxylup-20(29)-en-3-on-28-oic acid (1) inhibited
hormone-induced adipocyte differentiation and lipogenesis
in 3T3-L1 preadipocytes, alleviated DXM-induced adipo-
cyte dysfunction and restored glucose consuming ability in
DXM-treated 3T3-L1 adipocytes. It achieved this via down-
regulating hormone-stimulated gene transcription of PPARc
and C/EBPa in 3T3-L1 preadipocytes, and via reactivating
PI3K/Akt signaling and phosporylating AS160 in DXM-
treated 3T3-L1 adipocytes, thus leading to increased GLUT4
translocation and enhanced glucose transportation.
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